Fingerstick Blood Lithium Testing for Rapid Therapeutic Drug Monitoring in Psychiatry

Lithium remains one of the most widely used mood stabilizers for the treatment of bipolar disorder and other psychiatric conditions.

Because lithium has a narrow therapeutic window, regular therapeutic drug monitoring (TDM) is essential to maintain effective treatment while reducing the risk of lithium toxicity.

The **Lithium POCT Analyzer** provides a rapid and patient-friendly solution for lithium monitoring by enabling **fingerstick whole blood testing instead of traditional venous blood collection**.

Designed for decentralized healthcare environments, this point-of-care testing solution supports faster clinical decisions and more accessible psychiatric medication management.

 Key Features

 Fingerstick Whole Blood Testing

Traditional lithium monitoring requires venous blood collection and laboratory analysis.

The Lithium POCT Analyzer uses a small capillary blood sample obtained from a fingertip, reducing patient burden and simplifying repeated monitoring.

Benefits:

* Minimal sample volume
* Less invasive collection
* Improved patient acceptance
* Suitable for repeated monitoring

 Rapid Point-of-Care Results

The analyzer enables lithium concentration measurement closer to the patient.

Potential clinical benefits:

* Faster treatment decisions
* Reduced waiting time
* Improved clinical workflow
* Lower dependence on centralized laboratories

 Designed for Psychiatric Therapeutic Drug Monitoring

The system supports clinicians managing patients receiving lithium therapy.

Potential applications include:

* Bipolar disorder management
* Mood stabilization therapy
* Long-term lithium monitoring
* Medication safety assessment

Why Lithium Monitoring Matters

Lithium treatment requires careful monitoring because:

* Therapeutic and toxic concentrations are close
* Patient metabolism varies significantly
* Drug interactions may affect concentration
* Renal function influences lithium clearance

Without appropriate monitoring, patients may experience:

 Subtherapeutic exposure

Leading to:

* Reduced treatment effectiveness
* Increased risk of relapse

 Excessive exposure

Increasing the risk of:

* Tremor
* Nausea
* Confusion
* Neurological toxicity
* Severe adverse events

Therapeutic drug monitoring provides objective information for personalized treatment adjustment.

 Technology Principle

The Lithium POCT Analyzer is based on quantitative detection technology designed for therapeutic drug monitoring.

Workflow:

 Step 1

Collect a small fingerstick whole blood sample.

 Step 2

Apply sample to the test cartridge.

 Step 3

The analyzer measures lithium concentration.

 Step 4

Healthcare professionals interpret results for clinical decision-making.

Comparison With Traditional Lithium Testing

 Potential Clinical Settings

The Lithium POCT Analyzer can support:

 Psychiatric Hospitals

Routine lithium monitoring during treatment management.

 Community Mental Health Centers

Bringing monitoring closer to patients.

 Primary Care Networks

Supporting shared-care psychiatric management.

 Pharmacy-Based Healthcare

Potential future decentralized monitoring models.

 Telemedicine Programs

Combining remote consultation with local testing.

 Supporting the Future of Precision Psychiatry

Psychiatric medicine is moving toward personalized treatment strategies combining:

* Therapeutic drug monitoring
* Pharmacogenomics
* Digital biomarkers
* Artificial intelligence
* Remote healthcare

Lithium POCT provides an important biological measurement layer for precision mental healthcare.

 Global Trend: Moving TDM From Laboratory to Patient

Healthcare systems worldwide are increasingly adopting point-of-care testing.

The UK has initiated clinical evaluation of lithium point-of-care testing approaches, including feasibility studies investigating finger-prick lithium monitoring in routine care path